Latest

First Opinion Fengting Yan, Binay Shah, and Siddhartha Yadav

A new moonshot initiative to fight cervical cancer in the Indo-Pacific region is missing something

Health tech Nicholas St. Fleur

What YouTube Health is doing to combat misinformation and promote evidence-based content

Pharmalot Ed Silverman

STAT Plus: Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals

First Opinion Jared E. Boyce and Faith Crittenden

Pediatrics is becoming medicine’s largest skeleton crew

First Opinion Podcast Alissa Ambrose

A conversation on healing ‘spiritual injury’

Politics John Wilkerson

STAT Plus: It might be now or never for the BIOSECURE Act

Health Nicholas St. Fleur

Vanessa Kerry is on a mission to make the health care system resilient to climate change

Health Lizzy Lawrence

Trump taps biotech investor Jim O’Neill for HHS deputy secretary

Health Rachel Cohrs Zhang

Trump picks Stanford’s Jay Bhattacharya to lead NIH

Exclusive Allison DeAngelis

STAT Plus: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger

In the Lab Andrew Joseph

STAT Plus: New report urges guidelines — and some restrictions — on stem cell-based embryo models

Health Helen Branswell

Case of bird flu infection in British Columbia is still a mystery, for now

The Readout Adam Feuerstein

Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news

Business Tara Bannow

STAT Plus: Biden administration wants to rein in use of AI in Medicare Advantage, among other fixes

Biotech Jason Mast

STAT Plus: Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases

Health tech Brittany Trang

STAT Plus: Government watchdog calls out HHS for not auditing health care’s privacy compliance since 2017

Biotech Andrew Joseph

STAT Plus: Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness

Politics Rachel Cohrs Zhang

Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound

Politics Eric Boodman and Isabella Cueto

In the MAHA-verse, ex-Bernie die-hards and conservative moms find a political home

Pharma Alex Hogan

Inside the telehealth-fueled GLP-1 alternative market

First Opinion Alexa B. Kimball

The disappearance of empathetic touch in medicine

First Opinion David Balto

STAT Plus: Don’t expect Novo-Catalent merger investigation to fizzle out under the new Trump administration

Pharma Andrew Joseph

STAT Plus: Roche immunotherapy fails in lung cancer study, raising questions about drug’s target

Biotech Jason Mast

STAT Plus: Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial 

Adam's Take Adam Feuerstein

STAT Plus: Cassava Sciences and its Alzheimer’s drug are done. The damage lingers

Morning Rounds Theresa Gaffney

Trump nominates three key leaders in health care

Pharmalot Ed Silverman

STAT Plus: Minnesota becomes first state to release report on 340B drug discount program for ‘safety-net’ hospitals

The Readout Meghana Keshavan

STAT Plus: What to make of Trump’s health care nominees

A STAT Investigation Bob Herman, Casey Ross, Lizzy Lawrence, and Tara Bannow

STAT Plus: Health Care's Colossus: UnitedHealth pays its own physician groups considerably more than others